RxDoctor Payments Data

Christopher Schreier, DO

Family Medicine · Thorndale, PANPI 1164406344

Payments from drug & device makers

$7,407in general payments, 2019–2025

Across 426 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$807
  • AstraZeneca$806
  • Novo Nordisk$727
  • Lilly USA, LLC$515
  • Amgen$465
  • GSK$439
  • plus $4K from 39 others

What the payments were for

  • Consulting fees$1752%
  • Food & beverage$7,22598%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,407 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$410,117
Medicare patients
633
Services billed
8,960

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban271$197,941
OzempicSemaglutide75$106,413
JardianceEmpagliflozin105$79,525
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$57,502
FarxigaDapagliflozin Propanediol62$48,557
XareltoRivaroxaban65$45,803
JanuviaSitagliptin Phosphate74$43,831
TrulicityDulaglutide28$34,298
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$22,839
EntrestoSacubitril/Valsartan25$18,941
MounjaroTirzepatide13$15,780
Breo ElliptaFluticasone/Vilanterol26$11,918
Tresiba Flextouch U-100Insulin Degludec21$11,563
Atorvastatin Calcium624$9,018
Lantus SolostarInsulin Glargine,hum.Rec.Anlog87$8,528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$339$197,941271 claims
Novo NordiskOzempic$727$106,41375 claims
Boehringer IngelheimJardiance$204$79,525105 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy$439$76,704106 claims
Lilly USA, LLCTrulicity, Mounjaro$515$50,07841 claims
AstraZenecaFarxiga$806$48,55762 claims
Johnson & JohnsonXarelto$67$45,80365 claims
MerckJanuvia$149$43,83174 claims
NovartisEntresto$431$18,94125 claims
Astellas Pharma US IncMyrbetriq$116$7,68616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Thorndale

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →